Importance of the PaCO2 from 3 to 6 months after initiation of long-term non-invasive ventilation  by Tsuboi, Tomomasa et al.
Respiratory Medicine (2010) 104, 1850e1857ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedImportance of the PaCO2 from 3 to 6 months after
initiation of long-term non-invasive ventilationTomomasa Tsuboi a,*, Motoharu Ohi b, Toru Oga a, Kazuko Machida c,
Yuichi Chihara d, Yuka Harada d, Kenichi Takahashi e, Kensuke Sumi f,
Tomohiro Handa g, Akio Niimi d, Michiaki Mishima d, Kazuo Chin aaDepartment of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin
Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
b Sleep Medical Center, Osaka Kaisei Hospital, 1-6-10 Miyahara, Yodogawa-ku, Osaka 532-0003, Japan
cDepartment of Respiratory Medicine, National Tokyo Hospital, 3-1-1 Takeoka, Kiyose, Tokyo 204-8585, Japan
dDepartment of Respiratory Medicine, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku,
Kyoto 606-8507, Japan
eDepartment of Respiratory Medicine, Red Cross Otsu Hospital, 1 Nagara, Otsu, Shiga 520-8511, Japan
fDepartment of Respiratory Medicine, National Hospital Organization Minami-Kyoto Hospital, 11 Naka-Ashihara, Joyo,
Kyoto 610-0113, Japan
gDepartment of Rehabilitation, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
Received 19 January 2010; accepted 27 April 2010
Available online 26 May 2010KEYWORDS
Chronic respiratory
failure;
Home mechanical
ventilation;
Non-invasive positive
pressure ventilation;
Partial pressure of
carbon dioxide;
Restricted thoracic
disease* Corresponding author. Tel.: þ81 7
E-mail address: tomomasa@kuhp.k
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.04.027Summary
Background: The level at which arterial carbon dioxide tension (PaCO2) a few months after
introduction of long-term non-invasive positive pressure ventilation (NPPV) is associated with
a favorable prognosis remains uncertain.
Methods: Data on 184 post-tuberculosis patients with chronic restrictive ventilatory failure
who were receiving long-term domiciliary NPPV were examined retrospectively. Average PaCO2
3e6 months after NPPV (3- to 6-mo PaCO2) and potential confounders were analyzed with
discontinuation of long-term NPPV as the primary outcome. The effects of 3- to 6-mo PaCO2
on annual hospitalization rates due to respiratory deterioration from 1 year before to 3 years
after the initiation of NPPV were examined. The effect of the difference between the PaCO2
value at the start of NPPV (0-mo PaCO2) and the PaCO2 value 3- to 6-mo later (d-PaCO2) on
continuation rates for NPPV was also assessed in patients who initiated NPPV while in a chronic
state.
Results: Patients with relatively low 3- to 6-mo PaCO2 values maintained a relatively low PaCO2
6e36 months after NPPV (p < 0.0001) and had significantly better continuation rates (p < 0.03)
and lower hospitalization rates from the 1st to 3rd year of NPPV (p Z 0.008, 0.049, 0.009,5 751 3852; fax: þ81 75 751 3854.
yoto-u.ac.jp (T. Tsuboi).
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PaCO2 after initiation of long-term NPPV 1851respectively) than those with higher levels. The 0-mo PaCO2 (pZ 0.26) or d-PaCO2 (pZ 0.86)
had no predictive value.
Conclusion: A relatively low 3- to 6-mo PaCO2 value was predictive of long-term use of NPPV.
The target values for 3- to 6-mo PaCO2 may, therefore, be less than 60 mmHg in post-tubercu-
losis patients, although more studies are needed.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Domiciliary non-invasive positive pressure ventilation
(NPPV) has been widely used in the treatment of patients
with chronic hypercapnic respiratory failure.1e7 NPPV has
been shown to improve gas exchange, probably due to
increased ventilatory response to carbon dioxide (CO2) in
patients with chronic obstructive pulmonary disease
(COPD)8 and restrictive thoracic disease (RTD) including
pulmonary tuberculosis sequelae.9,10 Arterial blood gases
(ABGs) were reported to be stabilized a few months after
NPPV and maintained over several years in patients with
COPD1 and RTD.1,3,4,11 In patients with RTD, a higher
nighttime PaCO2 measured before the start of long-term
NPPV was shown to be a significant independent predictor
of mortality.12 In contrast, a higher daytime PaCO2 at the
start of NPPV (0-mo PaCO2) was not associated with a poor
prognosis in patients with RTD12 or COPD.13
Generally, ABG values and the general condition are
unstable in patients during the pre-NPPV period even in
those who started NPPV while in a chronic state. However,
gas exchange and the clinical state markedly stabilize after
institution of long-term NPPV. According to our clinical
experience, medication and ventilator settings seldom
needed to be changed after the clinical condition of
patients was stabilized by NPPV treatment. Therefore, as
prognostic factors, parameters after a few months of NPPV
seem to be more important and reliable than those before
starting NPPV. However, to the best of our knowledge, no
report has assessed PaCO2 a few months after the intro-
duction of long-term NPPV as a possible prognostic factor.
We hypothesized that patients with a relatively low mean
value of PaCO2 measured between 3 and 6 months after
introductionof long-termNPPV (3- to6-moPaCO2)wouldhave
higher continuation rates of NPPV and lower hospitalization
rates than those with a relatively high 3- to 6-mo PaCO2. We
retrospectively examined the effects of the 3- to 6-mo PaCO2
level on continuation of NPPV in post-tuberculosis patients.
Thus, we wanted to determine which levels of PaCO2 after
a few months of NPPV were suitable for those patients.
Methods
Patients
All post-tuberculosis patients who had started NPPV at 6
hospitals affiliated with Kyoto University Hospital and the
National Tokyo Hospital from June 15, 1990 to August 2, 2007
were included in this retrospective study. All patients had
chronic respiratory failure with hypercapnia. The NPPV
therapy was begun either after an acute episode or duringthe chronic state. The decision for initiation of NPPV was
based on clinical symptoms with persistent hypercapnia
during daytime (PaCO2 > 45 mmHg) and/or nocturnal hypo-
ventilation and/or clinical instability with recurrent hospi-
talizations. Patients with other causes of chronic respiratory
failure such as neuromuscular disorders, obesity hypo-
ventilation syndrome, bronchiectasis, idiopathic scoliosis, or
COPD were excluded.
The patients were followed until November 30, 2007.
Clinical assessmentswere performedat theendof every year
from 1995 to 2002, in December 2004 and in December 2007.
The patients were divided into 3 groups according to 3- to
6-mo PaCO2 levels (Group-1, 60 mmHg>, n Z 79; Group-2,
60-70 mmHg, n Z 61; Group-3, >70 mmHg, n Z 23).
Measurement of 3- to 6-mo PaCO2 could not be performed in
19 other patients who otherwise met criteria for study entry
because of clinical instability at the time or because they did
not attend outpatient clinic. The patients who started long-
term NPPVwhile in a chronic state were divided into 3 groups
according to the difference between 0-mo PaCO2 and 3- to
6-mo PaCO2 (d-PaCO2) (Group-d1,>16mmHg, nZ 33; Group-
d2, 8e16 mmHg, n Z 29; Group-d3, 8 mmHg>, n Z 28).
Patients in the present study were also subjects of our
previous study concerning ventilator modes.7
Measurements
Data on age at the start of NPPV, gender, presence of
pulmonary lesions, duration of long-term oxygen therapy
(LTOT) before the start of NPPV, status on introduction of
NPPV (i.e., acute or chronic state), ventilator mode (assisted
or controlled mode), other ventilator settings such as inspi-
ratory positive airway pressure (IPAP), expiratory positive
airway pressure (EPAP), respiratory rate (fR), and tidal
volume (VT), body-mass index (BMI), vital capacity
(percentage of predicted), forced expiratory volume in 1 s
over forced vital capacity (FEV1/FVC), and concurrent use of
LTOT after the start of NPPV were all examined and/or
documented fordeterminationof risk factors.Annualnumber
of hospitalizations due to respiratory deterioration (acute
bronchitis, pneumonia, spontaneous pneumothorax, chronic
disease progression, etc.) beginning from 1 year before to 3
years after the start ofNPPVwasalso included in this analysis.
Information on daytime ABGs was analyzed from 12
months before the start of NPPV to the observable end-
point if available. Determinations of ABGs were made with
the patient in the supine position breathing room air or
prescribed oxygen without NPPV support. ABGs were
obtained in patients who were in a stable condition without
exacerbation except for those obtained at the start of NPPV
from patients who had begun administration of NPPV during
an acute state.
1852 T. Tsuboi et al.All data on the clinical course of patients were collected
from clinical records.
Clinical protocol for introducing long-term NPPV
The precise criteria and procedure for introducing long-
term NPPV have been described elsewhere.7 At the start of
NPPV, volume preset ventilators were utilized with custom
fabricated nasal masks14 or with commercially available
interfaces. Pressure preset ventilators using bilevel PAP
devices were applied with commercially available inter-
faces. Supplemental oxygen was added to NPPV to maintain
an arterial oxygen saturation >95% during diurnal NPPV and
>90% during nocturnal NPPV.
This study was approved by the Ethics Committee of
Kyoto University, and individual consent was not obtained
as stipulated by the Committee. According to the recom-
mendation of the Ethics Committee of Kyoto University, the
protocol of this study is posted on the website of our
institute and all inquiries are answered.
Follow-up
In Japan, patients receiving long-term NPPV and/or LTOT
must attend outpatient clinic each month. ABG analysis and
chest X-ray were usually performed every 3e6 months.
Statistical analysis
Means and standard deviations are reported for patients’
characteristics and ventilator settings. One-way factorial
analysis of variance (ANOVA) and post-hoc analysis (Scheffe
test) were used for continuous variables and the 2  3
contingency table and chi-square tests for categorical vari-
ables were used to compare differences in patients’ char-
acteristics amongGroup-1 to -3. Comparisonsof continuation
rates of long-term NPPV by risk factors including 3- to 6-mo
PaCO2 levels were performed using univariate and multivar-
iate Cox proportional hazards regression analyses. 0-mo
PaCO2 values during periods without respiratory deteriora-
tion could be obtained only in patients starting NPPVwhile in
a chronic state. Therefore, comparison of continuation rates
of NPPV according to risk factors including d-PaCO2 were
performed in thosewho startedNPPVwhile ina chronic state.
Continuation rates of long-term NPPV were also assessed
using KaplaneMeier analyses (log-rank test). Among the
three groups (Group-1 to -3), comparison of annual hospi-
talization rates was performed using one-way factorial
ANOVA and post-hoc analysis (Scheffe test). To evaluate
differences in PaCO2 over time among those three groups,
repeated-measures ANOVA and post-hoc analysis (Scheffe
test) were used.
Results
Patient characteristics
A total of 184 patients who continued receiving NPPV for
more than 2 months were available for follow-up. Since two
patients discontinued NPPV due to improvement inhypercapnic respiratory failure, 182 patients were avail-
able for final analysis. Table 1 shows patients’ character-
istics in the 3 groups according to 3- to 6-mo PaCO2 levels.
Overall, patientswere characterized by severe restrictive
ventilatory failure, severe hypercapnia, moderate malnu-
trition and unstable clinical conditions. At the start of NPPV,
% predicted VC was higher and the duration of LTOT before
the start of NPPV was shorter in Group-1 patients than in
those in Group-2 or -3. Among the patients starting NPPV
while in a chronic state, Group-2 or -3 patients were more
acidotic and more hypercapnic at the start of NPPV than
Group-1 patients. As to ventilator settings, IPAP and fR were
higher in patients in Group-2 than in Group-1.
Overall outcome
Two patients discontinued NPPV due to improvement as
mentioned above. Outcome in the remaining 182 was as
follows. Two patients temporarily discontinued NPPV for
several months and then restarted. After the long-term use
of NPPV, 15 patients switched to long-term tracheostomy
positive pressure ventilation (TPPV) for amean (SD) duration
of 2.17 (2.28) y. As of December 2007, 85 patients had died, 2
were receiving TPPV, and 95 were continuing use of NPPV.
Time course of PaCO2 before and after NPPV
Comparisons of the time course of PaCO2 between patients
starting NPPVwhile in an acute state or in a chronic state are
shown in Fig. 1-a. Differences between the two groups were
only noted at the start of NPPV. The comparison of trends of
PaCO2 among patients divided by 3- to 6-mo PaCO2 levels
(Groups-1 to -3) is shown inFig. 1-b. From6 to36months after
initiation of NPPV, patients with relatively low 3- to 6-mo
PaCO2 levels had relatively lower PaCO2 values with signifi-
cance than those with relatively high 3- to 6-mo PaCO2 levels
(p Z 0.0004). Post-hoc analysis showed significant differ-
ences between Groups 1 and 2 (p< 0.0001), between Groups
2 and 3 (pZ 0.02), and between Groups 1 and 3 (p< 0.0001).
Comparison of continuation rate of long-term NPPV
use among all cases
In the univariate analysis, female gender, a higher BMI, no
parenchymal pulmonary lesions, lower annual hospitaliza-
tion rates due to respiratory deterioration before NPPV,
a controlledmode, and relatively low 3- to 6-mo PaCO2 levels
were all significantly associated with higher continuation
rates of NPPV (Table 2). Patients with a longer duration of
LTOT before NPPV tended to have higher continuation rates
of NPPV (p Z 0.11). Ventilator settings such as IPAP, EPAP,
and fR were not related to continuation rates of NPPV.
Multivariate analysis showed that controlled ventilation,
a higher BMI, female gender, and relatively low 3- to 6-mo
PaCO2 levels were all significantly associated with higher
continuation rates of NPPV (Table 3).
Results of the KaplaneMeier analysis showed significantly
increased continuation rates of long-term NPPV in patients
with relatively low 3- to 6-mo PaCO2 levels (p Z 0.0003;
Fig. 2). The 5- and 8-year probabilities of continuing NPPV for
Group-1 were 70.1% and 56.0%, respectively, those for
Table 1 Patients’ characteristics at beginning of long-term NPPV.
3- to 6-mo PaCO2 levels Group-1 Group-2 Group-3 p Value
<60 mmHg 60e70 mmHg > 70 mmHg
(n) 79 61 23
Age (y) 68.1 (9.0) 69.9 (6.7) 69.3 (6.7) 0.42
Gender (Female/Male) 36/43 31/30 9/14 0.61
BMI (kg/m2) 19.3 (3.7) 17.9 (3.4) 19.3 (3.0) 0.06
% Predicted VC (%) 34.7 (8.6) 30.5 (7.8) * 29.5 (5.5) * 0.004
FEV1/FVC (%) 70.7 (16.4) 74.9 (16.1) 71.4 (13.4) 0.33
Pulmonary lesions (þ/) 69/10 61/0 23/0 0.004
Annual hospitalization rate due to respiratory
deterioration before NPPV
1.27 (0.96) 1.61 (1.07) * 1.43 (0.99) 0.14
Patients’ state (Acute/Chronic) 32/47 29/32 10/13 0.71
Duration of LTOT before NPPV (y) 3.7 (3.8) 6.4 (5.0)* 7.7 (4.7)* <0.0001
Use of LTOT after NPPV (þ/) 71/8 60/1 22/1 0.11
Oxygen supply during spontaneous breathing
(l/min.)
1.1 (0.6) 1.3 (0.6) 1.4 (0.6) 0.06
Ventilator mode (Assisted/Controlled) 31/48 22/39 12/11 0.40
Bilevel PAP n Z 64 n Z 53 n Z 22
IPAP (cmH2O) 14.2 (4.1) 16.2 (3.4) * 16.3 (3.0) 0.01
EPAP (cmH2O) 3.6 (1.1) 3.8 (1.3) 4.3 (0.7) * 0.05
Respiratory rate 20.3 (4.5) 22.2 (3.9) 19.9 (4.0) 0.02
Volume preset n Z 15 n Z 8 n Z 1
Tidal Volume (ml) 578 (116) 533 (81) 620 0.54
Respiratory rate 22.5 (4.5) 25.6 (5.4) 20 0.27
Oxygen supply during NPPV (l/min.) 1.6 (0.8) 1.8 (1.0) 1.8 (0.7) 0.28
ABGs during spontaneous breathing at start of
NPPV (NPPV initiated during acute state)
n Z 32 n Z 29 n Z 10
pH 7.32 (0.06) 7.30 (0.05) 7.34 (0.03) 0.16
PaO2 (mmHg) 63.4 (18.4) 57.4 (18.9) 79.8 (21.9)# 0.01
PaCO2 (mmHg) 83.0 (20.9) 89.1 (15.7) 90.2 (13.6) 0.34
HCO3
 (mmol/l) 41.4 (6.5) 42.3 (9.4) 46.9 (6.4) 0.17
ABGs during spontaneous breathing at start of
NPPV (NPPV initiated during chronic state)
n Z 47 n Z 32 n Z 13
pH 7.36 (0.04) 7.33 (0.04)* 7.33 (0.04)* <0.0001
PaO2 (mmHg) 71.1 (15.8) 82.0 (14.9)* 83.3 (22.4) 0.01
PaCO2 (mmHg) 64.6 (9.7) 81.6 (11.5)* 86.1 (10.8)* <0.0001
HCO3
 (mmol/l) 35.9 (3.9) 42.6 (5.2)* 44.5 (5.1)* <0.0001
Values given as mean (SD), *p < 0.05 (compared to Group-1), #p < 0.05 (compared to Group-2).
3- to 6-mo PaCO2, mean value of PaCO2 measured between 3 and 6 months after introduction of long-term NPPV; BMI, body-mass index;
VC, vital capacity; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NPPV, non-invasive positive pressure ventilation;
LTOT, long-term oxygen therapy; bilevel PAP, bilevel positive airway pressure; IPAP, inspiratory positive airway pressure; EPAP, expi-
ratory positive airway pressure; ABGs, arterial blood gas analyses; PaO2, PaCO2, arterial oxygen and carbon dioxide tensions; HCO3
,
bicarbonate.
PaCO2 after initiation of long-term NPPV 1853Group-2 were 55.0% and 24.3%, respectively, and those for
Group-3 were 35.6% and 0%, respectively.
Comparison of continuation rate of NPPV in
patients starting NPPV during the chronic state
Univariate analysis showed that a controlled mode
(p Z 0.005), female gender (p Z 0.04), and relatively low
3- to 6-mo PaCO2 levels (p Z 0.03) were all significantly
associated with higher continuation rates of long-term
NPPV while the 0-mo PaCO2 (p Z 0.26) and d-PaCO2 values
(p Z 0.86) had no such significant association. By
KaplaneMeier analysis, a relatively low 3- to 6-mo PaCO2level was significantly associated with higher continuation
rates of long-term NPPV (p Z 0.026; Fig. 3).
In multivariate analysis according to risk factors of
ventilator mode, 3- to 6-mo PaCO2 levels and gender, the
controlled mode (p Z 0.007) and relatively low 3- to 6-mo
PaCO2 levels (p Z 0.04) were significantly associated with
higher continuation rates of long-term NPPV.
Comparison of annual hospitalization rate among
three groups divided by 3- to 6-mo PaCO2 levels
Patients with relatively low 3- to 6-mo PaCO2 levels had
significantly lower hospitalization rates due to respiratory
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Figure 1 a. Time course of PaCO2 values before and after NPPV. Comparison between patients with initiation of NPPV in either an
acute or chronic state. Data are presented as mean (SD). No significant difference was noted except for values at the start of NPPV.
#p < 0.05 (compared with patients starting NPPV while in a chronic state). b. Time course of PaCO2 values before and after NPPV.
Comparison among patients grouped according to the average PaCO2 3e6 months after introduction of long-term NPPV (3- to 6-mo
PaCO2) (Group-1, 60 mmHg>; Group-2, 60e70 mmHg; Group-3, >70 mmHg). Data are presented as mean (SD). From 6 to 36 months
after initiation of NPPV, patients with relatively high 3- to 6-mo PaCO2 values had significantly higher PaCO2 than those with
relatively low 3- to 6-mo PaCO2 (pZ 0.0004). #p < 0.0001 (compared to group-1), þþpZ 0.02 (compared to group-2) by post-hoc
analysis.
1854 T. Tsuboi et al.deterioration than those with relatively high 3- to 6-mo
PaCO2 levels. Mean (SD) of hospitalization rates in Group-1
to -3 were 0.23 (0.60), 0.31 (0.62), and 0.82 (1.53),
respectively, in the 1st year, 0.21 (0.53), 0.41 (0.63), and
0.53 (0.62), respectively, in the 2nd year, and 0.18 (0.43),
0.49 (0.68), and 0.50 (0.52), respectively, in the 3rd year of
long-term NPPV. There was no significant difference in
hospitalization rates for the year preceding NPPV in Group-
1 to -3 1.27 (0.96), 1.61 (1.07), and 1.43 (0.99),
respectively.Discussion
In the present study, patients that had relatively low
daytime PaCO2 levels a few months after NPPV hadsignificantly higher continuation rates of NPPV and signifi-
cantly lower hospitalization rates due to respiratory dete-
rioration from the first to the third years of NPPV. Such
patients had also maintained relatively low PaCO2 levels
from 6 to 36 months after NPPV. Neither the PaCO2 level at
the start of NPPV nor improvement in PaCO2 after use of
NPPV was a significant predictive variable.
In general, patients with hypercapnic respiratory failure
started long-term NPPV during either an acute or chronic
state.1,2 The patients in the chronic state might not have
been completely stable while receiving only LTOT. Actually,
most of our patients who were considered to have a chronic
status had experienced gradual deterioration of their
symptoms over a long period even though their respiratory
condition was not acutely aggravated. Their PaCO2 had
increased slowly during the pre-NPPV period as shown in
Table 2 Univariate modality model.
Variable Category (n) HR (95%CI) p Value
Gender Female 85 0.53 (0.34e0.83) 0.005
Male 97 Reference
Age (y) <69 89 0.92 (0.60e1.42) 0.70
69& 93 Reference
BMI (kg/m2) 18.6& 83 0.58 (0.37e0.91) 0.02
<18.6 79 Reference
% predicted VC (%) <31.4 81 0.89 (0.56e1.41) 0.62
31.4& 81 Reference
FEV1/FVC (%) <70 68 0.87 (0.55e1.39) 0.56
70& 95 Reference
Pulmonary lesions () 14 0.25 (0.08e0.81) 0.02
(þ) 168 Reference
Patients’ status Acute 79 0.78 (0.51e1.21) 0.27
Chronic 103 Reference
Hospitalization rate due to acute
respiratory episodes before NPPV
0e1 118 0.65 (0.42e0.99) 0.04
2& 64 Reference
Duration of LTOT before NPPV (y) 4.5& 91 0.70 (0.46e1.08) 0.11
<4.5 91 Reference
Use of LTOT after NPPV (þ) 170 0.79 (0.32e1.96) 0.62
() 12 Reference
Ventilator mode Controlled 106 0.54 (0.35e0.83) 0.01
Assisted 76 Reference
Ventilator settings
IPAP (cmH2O) Continuous variable 162 0.99 (0.94e1.05) 0.82
EPAP (cmH2O) Continuous variable 162 0.92 (0.78e1.09) 0.33
Respiratory rate (/min.) Continuous variable 182 0.96 (0.91e1.01) 0.14
3- to 6-mo PaCO2 (mmHg) 0.0006
<60 79 0.29 (0.16e0.54) 0.0001
60e70 61 0.47 (0.26e0.87) 0.02
70< 23 Reference e
PaCO2 after initiation of long-term NPPV 1855Fig. 1-a. Midgren had reported the same findings concerning
PaCO2 during the pre-NPPV period in post-polio patients.
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Therefore, even in patients for whom non-invasive venti-
lation was initiated during the chronic state, the ABG level
before NPPV might be inappropriate as a predictive vari-
able. Furthermore, since the elevated PaCO2 is effectivelyTable 3 Multivariate modality model.
Variable
Ventilator mode Controlle
Assisted
BMI (kg/m2) 18.6&
<18.6
3- to 6-mo PaCO2 (mmHg)
<60
60e70
70<
Gender Female
Male
Pulmonary lesions e
þ
Hospitalization rate due to acute respiratory
episodes before NPPV
0e1
2&corrected within a few months of NPPV, it is unlikely to
have any lasting predictive value for latter outcome.
The persistent CO2 retention in patients with chronic
ventilatory failure might reflect an adaptive mechanism
that permits a lower level of alveolar ventilation, thus
resulting in unloading of the overburdened respiratoryn HR (95%CI) p Value
d 106 0.41 (0.25e0.68) 0.0005
76 Reference
83 0.54 (0.32e0.92) 0.02
79 Reference
0.03
79 0.37 (0.18e0.77) 0.01
61 0.44 (0.21e0.89) 0.02
23 Reference e
85 0.59 (0.36e0.97) 0.04
97 Reference
14 0.30 (0.09e1.05) 0.06
168 Reference
118 0.81 (0.49e1.34) 0.41
64 Reference
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Figure 2 KaplaneMeier curves of continuation rates of long-
term NPPV in all patients. Patients were divided into 3 groups
according to the average PaCO2 3e6 months after introduction
of long-term NPPV (3- to 6-mo PaCO2) (Group-1, 60 mmHg>;
Group-2, 60e70 mmHg; Group-3, >70 mmHg). Patients with
relatively low 3- to 6-mo PaCO2 values had a significantly better
prognosis (log-rank test, p Z 0.0003).
1856 T. Tsuboi et al.muscles leading to decreased dyspnea, particularly while
LTOT is administered.16,17 It is presumed by some that this
compensatory mechanism reveals the wisdom of nature.17
However, ventilatory support such as NPPV should be
implemented if hypercapnic ventilatory failure progresses
over limits of this compensation.8e10,18e21 An improvement
in daytime PaCO2 after initiation of NPPV was shown to be
correlated with the change in PaCO2 while receiving
nocturnal NPPV18,22 and the principal mechanism under-
lying the long-term improvement in daytime PaCO2 was
demonstrated to be an increased ventilatory response to
CO2.
8e10
The present study showed that patients with relatively
low 3- to 6-mo PaCO2 values were able to maintain rela-
tively low daytime PaCO2 levels for several years and that
the continuation rate of NPPV was higher and the hospi-
talization rate due to respiratory deterioration was lower
in these patients than in those with relatively high 3- to 6-
mo PaCO2 values. Elliott emphasized that hypercapnia is
a poor prognostic sign and that more aggressive620.0=p
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Figure 3 KaplaneMeier curves for continuation rates of long-
term NPPV in patients who began NPPV during a chronic state.
Comparisons were made among patients who were divided into
3 groups according to the average PaCO2 at 3e6 months after
introduction of long-term NPPV (3- to 6-mo PaCO2) (Group-1,
60 mmHg>; Group-2, 60e70 mmHg; Group-3, >70 mmHg).
Relatively low 3- to 6-mo PaCO2 was significantly associated
with higher continuation rates (log-rank test, p Z 0.026).ventilation might have resulted in a larger decrease in
daytime PaCO2.
21 Tuggey et al. showed that greater
minute ventilation can be achieved by using higher IPAP or
larger VT during controlled NPPV.20 Reduction in daytime
PaCO2 within the first 3 months of NPPV was reported to
be positively correlated with support pressure.11 Windisch
et al. found that the PaCO2 value during controlled NPPV
using high fR and high inspiratory pressure decreased to
a normocapnic level.18 They also suggested that nocturnal
NPPV with ventilator settings aimed at maximally
decreasing PaCO2 could decrease daytime PaCO2 suffi-
ciently and provide additional clinical benefits such as
prolongation of life.17,19 Dellborg et al. showed that
improvements in morning PaCO2 during NPPV correlated
significantly with improvements in symptoms and sleep
quality after 9 months of NPPV, which indicates the
importance of lowering PaCO2 during nocturnal NPPV.
23
These reports support the beneficial effect of nocturnal
high intensity NPPV in reducing nocturnal and, therefore,
daytime PaCO2 values.
The present study also showed that patients with rela-
tively high 3- to 6-mo PaCO2 values retained relatively high
PaCO2 levels throughout their clinical course, although
long-term NPPV decreased the PaCO2 level in all 3 groups
(Fig. 1-b). Patients with relatively high 3- to 6-mo PaCO2
levels had longer periods of LTOT before the initiation of
NPPV and more severe ventilatory defects at the start of
NPPV. These results indicate the possibility that patients
with more advanced disease tend to have higher daytime
PaCO2 than those with less advanced disease, with and
without application of long-term NPPV. Therefore, it
remains unclear whether reducing the nocturnal PaCO2 to
a nearly normocapnic level in every patient is possible.
Besides, whether a greater reduction in daytime PaCO2 is
beneficial in every patient has not been clarified. The
excessive resetting of PaCO2 might theoretically augment
patients’ dyspnea in spontaneous breathing because there
is a possibility that, to keep PaCO2 at the set low level,
patients have to increase and maintain ventilation
exceeding the capacity of their respiratory muscles.
Our study has several limitations. Beginning of the use of
and prevalence of the use of NPPV were delayed for more
than five years in Japan compared to European countries.24
Therefore, in many post-tuberculosis patients with hyper-
capnic respiratory failure, LTOT had been the only available
treatment and their PaCO2 values had already risen to
extremely high levels before the start of long-term NPPV.7
For this reason, in some of our patients, the daytime
PaCO2 value could not be reduced below 60 mmHg with
long-term NPPV although both IPAP levels and improvement
in daytime PaCO2 values were almost equivalent to those of
previous studies.1,2,4,9e11,25,26 The patients in those
previous studies had lower PaCO2 values at the start of
NPPV than our patients and it was not unexpected that
their PaCO2 values after NPPV was lower than those of our
patients.1,2,4,9e11,25,26 In such patients, the target values of
PaCO2 after NPPV can be supposed to be much lower than
for our patients.
In 92% of our patients LTOT was concomitantly used
immediately after the initiation of NPPV. This percentage
appears to be high, but we think that the difference in
percentage of LTOT usage between a previous study12 and
PaCO2 after initiation of long-term NPPV 1857our study might be attributed to higher PaCO2 and lower
PaO2 of our patients after initiation of long-term NPPV.
In conclusion,wefirst found that patientswith a relatively
lowPaCO2a fewmonthsafterNPPVmaintained relatively low
PaCO2 levels for several years and that PaCO2 a few months
after the initiation of NPPV is a significant predictive variable
for rates of continuation of NPPV and hospitalization rates
due to respiratory deterioration. The target level of daytime
PaCO2 after NPPV should be less than 60 mmHg in patients
with extremely severe hypercapnia like ours, although more
studies are needed to clarify to what extent the daytime
PaCO2 value should be reduced in individual patients with
moderate to severe hypercapnia.
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